Published in Clin Endocrinol (Oxf) on January 12, 2014
A descriptive study of adrenal crises in adults with adrenal insufficiency: increased risk with age and in those with bacterial infections. BMC Endocr Disord (2014) 0.86
Saving lives of in-patients with adrenal insufficiency: implementation of an alert scheme within the Newcastle-upon-Tyne Hospitals e-Prescribing platform. Clin Endocrinol (Oxf) (2014) 0.75
Academic medicine: a faltering engine. BMJ (2002) 8.12
Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med (2007) 6.58
Corticosteroid insufficiency in acutely ill patients. N Engl J Med (2003) 6.00
Improving clinical research. BMJ (2003) 5.23
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2008) 4.90
11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev (2004) 3.56
Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer (2009) 2.98
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
How should we rate research? BMJ (2006) 2.65
Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet (2004) 2.49
Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol (2010) 2.49
Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension (2012) 2.31
Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol (2009) 2.30
Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab (2006) 2.15
Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J Clin Endocrinol Metab (2010) 2.10
Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol (2002) 2.02
Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res (2002) 1.94
Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ (2010) 1.90
Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab (2011) 1.86
Premature mortality in patients with Addison's disease: a population-based study. J Clin Endocrinol Metab (2006) 1.75
Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models. Growth Horm IGF Res (2008) 1.72
Low birth size and final height predict high sympathetic nerve activity in adulthood. J Hypertens (2004) 1.72
11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol (2005) 1.70
Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS). J Steroid Biochem Mol Biol (2010) 1.63
Outcome of Cushing's disease following transsphenoidal surgery in a single center over 20 years. J Clin Endocrinol Metab (2012) 1.61
Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. J Clin Endocrinol Metab (2014) 1.61
No evidence for hepatic conversion of dehydroepiandrosterone (DHEA) sulfate to DHEA: in vivo and in vitro studies. J Clin Endocrinol Metab (2005) 1.59
Genotype-phenotype correlation in 153 adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: analysis of the United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE) cohort. J Clin Endocrinol Metab (2013) 1.58
Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet (2003) 1.58
Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res (2005) 1.58
Hexose-6-phosphate dehydrogenase knock-out mice lack 11 beta-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation. J Biol Chem (2005) 1.57
Estrogen regulation of growth hormone action. Endocr Rev (2004) 1.54
Mortality in patients with pituitary disease. Endocr Rev (2010) 1.48
The diagnosis and treatment of primary hyperaldosteronism in Germany: results on 555 patients from the German Conn Registry. Dtsch Arztebl Int (2009) 1.46
Intraoperative haemodynamic stability in patients with phaeochromocytoma--minimally invasive vs conventional open surgery. Clin Endocrinol (Oxf) (2006) 1.45
Deficits in the management of patients with adrenocortical carcinoma in Germany. Dtsch Arztebl Int (2010) 1.44
A comparative quality assessment of evidence-based clinical guidelines in endocrinology. Clin Endocrinol (Oxf) (2013) 1.42
The ontogeny of 25-hydroxyvitamin D(3) 1alpha-hydroxylase expression in human placenta and decidua. Am J Pathol (2002) 1.41
Investigating hypertension in a young person. BMJ (2009) 1.39
Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int (2008) 1.36
Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) (2004) 1.36
Minireview: hexose-6-phosphate dehydrogenase and redox control of 11{beta}-hydroxysteroid dehydrogenase type 1 activity. Endocrinology (2005) 1.35
Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J Clin Endocrinol Metab (2004) 1.33
High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab (2010) 1.31
Congenital isolated adrenocorticotropin deficiency: an underestimated cause of neonatal death, explained by TPIT gene mutations. J Clin Endocrinol Metab (2004) 1.29
11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes (2009) 1.29
The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab (2012) 1.29
Localization, age- and site-dependent expression, and regulation of 11β-hydroxysteroid dehydrogenase type 1 in skin. J Invest Dermatol (2010) 1.27
Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11 beta-hydroxysteroid dehydrogenase type 1. J Mol Endocrinol (2005) 1.26
Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients. Am J Med Sci (2010) 1.26
Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells. Clin Cancer Res (2006) 1.22
Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Oncogene (2004) 1.20
Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab (2005) 1.19
Expression profiles for steroidogenic enzymes in adrenocortical disease. J Clin Endocrinol Metab (2005) 1.19
Radiotherapy in adrenocortical carcinoma. Cancer (2009) 1.18
Deletion of hexose-6-phosphate dehydrogenase activates the unfolded protein response pathway and induces skeletal myopathy. J Biol Chem (2008) 1.18
Differential expression, function and response to inflammatory stimuli of 11beta-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation. Arthritis Res Ther (2006) 1.17
The long-term predictive accuracy of the short synacthen (corticotropin) stimulation test for assessment of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab (2005) 1.15
Regulation of lipogenesis by glucocorticoids and insulin in human adipose tissue. PLoS One (2011) 1.13
Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol (2013) 1.11
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J Clin Endocrinol Metab (2007) 1.11
The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab (2006) 1.11
NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases--a diagnostic tool? NMR Biomed (2010) 1.10
11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J Clin Endocrinol Metab (2009) 1.10
The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. Nat Rev Endocrinol (2013) 1.09
Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P. Mol Endocrinol (2007) 1.09
Androgen generation in adipose tissue in women with simple obesity--a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5. J Endocrinol (2004) 1.09
Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. Diabetes (2008) 1.08
Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab (2006) 1.08
Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab (2010) 1.07
Exploring the pathogenesis of IIH: an inflammatory perspective. J Neuroimmunol (2008) 1.06
Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome. Nat Clin Pract Endocrinol Metab (2005) 1.06
New selective inhibitors of steroid 11beta-hydroxylation in the adrenal cortex. Synthesis and structure-activity relationship of potent etomidate analogues. J Med Chem (2008) 1.05
Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol (2012) 1.05
Therapy of endocrine disease: Perspectives on the management of adrenal insufficiency: clinical insights from across Europe. Eur J Endocrinol (2013) 1.04
Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J Clin Endocrinol Metab (2008) 1.04
Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension (2012) 1.04
TP53 germline mutations in adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab (2011) 1.04
Glucocorticoids fail to cause insulin resistance in human subcutaneous adipose tissue in vivo. J Clin Endocrinol Metab (2013) 1.04
Weight loss increases 11beta-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue. J Clin Endocrinol Metab (2004) 1.03
Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur J Endocrinol (2008) 1.03
Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab (2003) 1.02
Adipophilin distribution and colocalization with lipid droplets in skeletal muscle. Histochem Cell Biol (2009) 1.02
11β-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects. Endocr Rev (2013) 1.01
Hexose-6-phosphate dehydrogenase contributes to skeletal muscle homeostasis independent of 11β-hydroxysteroid dehydrogenase type 1. Endocrinology (2010) 1.01
Dissociation of serum dehydroepiandrosterone and dehydroepiandrosterone sulfate in septic shock. J Clin Endocrinol Metab (2006) 1.01
Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab (2012) 1.00
Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin Endocrinol (Oxf) (2006) 1.00
Premature adrenarche: novel lessons from early onset androgen excess. Eur J Endocrinol (2011) 1.00
Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab (2002) 1.00
Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr Relat Cancer (2009) 1.00
Renal TLR4 mRNA expression correlates with inflammatory marker MCP-1 and profibrotic molecule TGF-β₁ in patients with chronic kidney disease. Nephron Clin Pract (2011) 1.00
Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation (2005) 0.99
Acupuncture for ovulation induction in polycystic ovary syndrome: a randomized controlled trial. Am J Physiol Endocrinol Metab (2013) 0.99
Identification of VDR-responsive gene signatures in breast cancer cells. Oncology (2007) 0.99
Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Mod Pathol (2010) 0.98
The GH/IGF-1 Axis in Obesity: Physiological and Pathological Aspects. Metab Syndr Relat Disord (2006) 0.98
Pituitary-interrenal interaction in zebrafish interrenal organ development. Mol Endocrinol (2006) 0.98
Reduced glucocorticoid production rate, decreased 5alpha-reductase activity, and adipose tissue insulin sensitization after weight loss. Diabetes (2008) 0.98